Linda L. Humphrey, MD, MPH; Mark Deffebach, MD; Miranda Pappas, MA; Bernadette Zakher, MBBS; Christopher G. Slatore, MD, MS
Potential Conflicts of Interest: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M13-1080.
Humphrey LL, Deffebach M, Pappas M, Zakher B, Slatore CG. Screening for Lung Cancer With Low-Dose Computed Tomography. Ann Intern Med. 2014;160:212. doi: 10.7326/L14-5003-3
Download citation file:
Published: Ann Intern Med. 2014;160(3):212.
As we noted in our article and the associated systematic review, overdiagnosis is a risk of lung cancer screening of uncertain magnitude. We do not believe that the Mayo Lung Project provides a valid estimate of overdiagnosis for many reasons, most of which we outlined in our report (1) and the prior review (2). More research in this important area is needed.
We rated the quality of the DLCST as moderate. Limitations that we identified included a lack of description of allocation concealment, as Drs. Brodersen, Dirksen, and Pedersen note. They state that patients were randomly assigned at their first visit. Allocation concealment was not described, only that patients were randomly assigned in block permutation form (3). In general, we rely on information in publications to evaluate trial quality. Furthermore, Saghir and associates note unequal follow-up in the DLCST when they state, “Information on lung cancer in the control group is not as up to date as in the screening group” (4).
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only